Fundamental Analysis of INHIBIKASE THERAPEUTICS INC(NASDAQ:IKT) stock

Fundamental Rating

Taking everything into account, IKT scores 2 out of 10 in our fundamental rating. IKT was compared to 565 industry peers in the Biotechnology industry. While IKT seems to be doing ok healthwise, there are quite some concerns on its profitability. IKT has a expensive valuation and it also scores bad on growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IKT has reported negative net income.

IKT had a negative operating cash flow in the past year.

IKT had negative earnings in each of the past 5 years.

IKT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of IKT (-208.31%) is worse than 91.09% of its industry peers.

Looking at the Return On Equity, with a value of -360.77%, IKT is doing worse than 77.18% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-208.31%
ROE	-360.77%
ROIC	N/A

ROA(3y)-79.46%

ROA(5y)-2911.53%

ROE(3y)-99.21%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IKT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IKT does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for IKT has been increased compared to 1 year ago.

IKT has more shares outstanding than it did 5 years ago.

IKT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 2.83 indicates that IKT is not a great score, but indicates only limited risk for bankruptcy at the moment.

The Altman-Z score of IKT (2.83) is better than 74.87% of its industry peers.

IKT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.83

ROIC/WACCN/A

WACC10.41%

2.3 Liquidity

IKT has a Current Ratio of 2.32. This indicates that IKT is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of IKT (2.32) is worse than 72.19% of its industry peers.

A Quick Ratio of 2.32 indicates that IKT has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 2.32, IKT is doing worse than 71.12% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.32
Quick Ratio	2.32

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IKT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.68%, which is quite impressive.

Looking at the last year, IKT shows a very negative growth in Revenue. The Revenue has decreased by -68.00% in the last year.

IKT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -42.21% yearly.

EPS 1Y (TTM)31.68%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%40.54%

Revenue 1Y (TTM)-68%

Revenue growth 3Y-28.07%

Revenue growth 5Y-42.21%

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.46% on average over the next years. This is a very strong growth

The Revenue is expected to decrease by -25.99% on average over the next years. This is quite bad

EPS Next Y83.73%

EPS Next 2Y38.85%

EPS Next 3Y24.46%

EPS Next 5YN/A

Revenue Next Year-100%

Revenue Next 2Y-41.42%

Revenue Next 3Y-25.99%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IKT. In the last year negative earnings were reported.

Also next year IKT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as IKT's earnings are expected to grow with 24.46% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y38.85%

EPS Next 3Y24.46%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IKT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INHIBIKASE THERAPEUTICS INC

NASDAQ:IKT (11/21/2024, 4:30:02 PM)

2.01

+0.03 (+1.52%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap135.05M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-208.31%
ROE	-360.77%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.32
Quick Ratio	2.32
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)31.68%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y83.73%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-68%

Revenue growth 3Y-28.07%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

INHIBIKASE THERAPEUTICS INC (IKT)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens